Regenlife has reached a new milestone in the clinical development of its technology for Alzheimer’s disease. The French company, which specialises in the research and development of innovative photobiomodulation and neuromodulation technologies for the prevention and treatment of neurodegenerative diseases, is opening a new private clinical trial centre at Biofortis in Nantes. This move aims to accelerate the recruitment of the 108 patients for the pivotal Light4Life trial, aged between 55 and 85 and suffering from mild to moderate Alzheimer’s disease. Nantes completes a clinical trial network already in place at Toulouse University Hospital, the centres in Lavaur and Castres, the Lariboisière and Broca hospitals (AP-HP) in Paris, and Lyon University Hospital.
Translated with DeepL.com (free version)